203
Views
26
CrossRef citations to date
0
Altmetric
Research Article

The ratio of a urinary tobacco-specific lung carcinogen metabolite to cotinine is significantly higher in passive than in active smokers

, , , &
Pages 491-497 | Received 11 Jul 2010, Accepted 16 Oct 2010, Published online: 03 Aug 2011

References

  • Anderson KE, Carmella SG, Ye M, Bliss RL, Le C, Murphy L, Hecht SS. (2001). Metabolites of a tobacco-specific lung carcinogen in nonsmoking women exposed to environmental tobacco smoke. j Natl Cancer Inst 93:378–381.
  • Anderson KE, Kliris J, Murphy L, Carmella SG, Han S, Link C, Bliss RL, Puumala S, Murphy SE, Hecht SS. (2003). Metabolites of a tobacco-specific lung carcinogen in nonsmoking casino patrons. Cancer Epidemiol Biomarkers Prev 12:1544–1546.
  • Benowitz N, Goniewicz ML, Eisner MD, Lazcano-Ponce E, Zielinska-Danch W, Koszowski B, Sobczak A, Havel C, Jacob P. 3rd(2010). Urine cotinine underestimates exposure to the tobacco-derived lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in passive compared with active smokers. Cancer Epidemiol Biomarkers Prev 19:2795–2800.
  • Berg JZ, Mason J, Boettcher AJ, Hatsukami DK, Murphy SE. (2010). Nicotine metabolism in African Americans and European Americans: variation in glucuronidation by ethnicity and UGT2B10 haplotype. j Pharmacol Exp Ther 332:202–209.
  • Berg JZ, von Weymarn LB, Thompson EA, Wickham KM, Weisensel NA, Hatsukami DK, Murphy SE. (2010). UGT2B10 genotype influences nicotine glucuronidation, oxidation, and consumption. Cancer Epidemiol Biomarkers Prev 19:1423–1431.
  • Bernert JT, Pirkle JL, Xia Y, Jain RB, Ashley DL, Sampson EJ. (2010). Urine concentrations of a tobacco-specific nitrosamine carcinogen in the U.S. population from secondhand smoke exposure. Cancer Epidemiol Biomarkers Prev 19:2969–2977.
  • Carmella SG, Han S, Fristad A, Yang Y, Hecht SS. (2003). Analysis of total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) in human urine. Cancer Epidemiol Biomarkers Prev 12:1257–1261.
  • Church TR, Anderson KE, Le C, Zhang Y, Kampa DM, Benoit AR, Yoder AR, Carmella SG, Hecht SS. (2010). Temporal stability of urinary and plasma biomarkers of tobacco smoke exposure among cigarette smokers. Biomarkers 15:345–352.
  • Goniewicz ML, Eisner MD, Lazcano-Ponce E, Zielinska-Danch W, Koszowski B, Sobczak A, Havel C, Jacob P, Benowitz NL. (2011). Comparison of urine cotinine and the tobacco-specific nitrosamine metabolite 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) and their ratio to discriminate active from passive smoking. Nicotine Tob Res 13:202–208.
  • Goniewicz ML, Havel CM, Peng MW, Jacob P 3rd, Dempsey D, Yu L, Zielinska-Danch W, Koszowski B, Czogala J, Sobczak A, Benowitz NL. (2009). Elimination kinetics of the tobacco-specific biomarker and lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol. Cancer Epidemiol Biomarkers Prev 18:3421–3425.
  • Hanson K, Allen S, Dayton R, Cao Q, Hatsukami DK. (2011). Smoking reduction after a failed quit attempt among adolescents. submitted.
  • Hatsukami D, Mooney M, Murphy S, LeSage M, Babb D, Hecht S. (2007). Effects of high dose transdermal nicotine replacement in cigarette smokers. Pharmacol Biochem Behav 86:132–139.
  • Hatsukami DK, Kotlyar M, Hertsgaard LA, Zhang Y, Carmella SG, Jensen JA, Allen SS, Shields PG, Murphy SE, Stepanov I, Hecht SS. (2010). Reduced nicotine content cigarettes: effects on toxicant exposure, dependence and cessation. Addiction 105:343–355.
  • Hatsukami DK, Lemmonds C, Zhang Y, Murphy SE, Le C, Carmella SG, Hecht SS. (2004). Evaluation of carcinogen exposure in people who used “reduced exposure” tobacco products. j Natl Cancer Inst 96:844–852.
  • Hecht SS. (1998). Biochemistry, biology, and carcinogenicity of tobacco-specific N-nitrosamines. Chem Res Toxicol 11:559–603.
  • Hecht SS. (2003). Carcinogen derived biomarkers: applications in studies of human exposure to secondhand tobacco smoke. Tob Control 13 (Suppl 1):i48–i56.
  • Hecht SS. (2006). A biomarker of exposure to environmental tobacco smoke (ETS) and Ernst Wynder’s opinion about ETS and lung cancer. Prev Med 43:256–260.
  • Hecht SS. (2008). Progress and challenges in selected areas of tobacco carcinogenesis. Chem Res Toxicol 21:160–171.
  • Hecht SS, Carmella SG, Chen M, Dor Koch JF, Miller AT, Murphy SE, Jensen JA, Zimmerman CL, Hatsukami DK. (1999). Quantitation of urinary metabolites of a tobacco-specific lung carcinogen after smoking cessation. Cancer Res 59:590–596.
  • Hecht SS, Carmella SG, Le KA, Murphy SE, Boettcher AJ, Le C, Koopmeiners J, An L, Hennrikus DJ. (2006). 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol and its glucuronides in the urine of infants exposed to environmental tobacco smoke. Cancer Epidemiol Biomarkers Prev 15:988–992.
  • Hecht SS, Carmella SG, Murphy SE, Akerkar S, Brunnemann KD, Hoffmann D. (1993). A tobacco-specific lung carcinogen in the urine of men exposed to cigarette smoke. n Engl j Med 329:1543–1546.
  • Hecht SS, Murphy SE, Carmella SG, Zimmerman CL, Losey L, Kramarczuk I, Roe MR, Puumala SS, Li YS, Le C, Jensen J, Hatsukami DK. (2004). Effects of reduced cigarette smoking on the uptake of a tobacco-specific lung carcinogen. j Natl Cancer Inst 96:107–115.
  • Hecht SS, Ye M, Carmella SG, Fredrickson A, Adgate JL, Greaves IA, Church TR, Ryan AD, Mongin SJ, Sexton K. (2001). Metabolites of a tobacco-specific lung carcinogen in the urine of elementary school-aged children. Cancer Epidemiol Biomarkers Prev 10:1109–1116.
  • Hukkanen J, Jacob P 3rd, Benowitz NL. (2005). Metabolism and disposition kinetics of nicotine. Pharmacol Rev 57:79–115.
  • International Agency for Research on Cancer. (2004). Tobacco Smoke and Involuntary Smoking. In IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, vol. 83 pp 1191–1413, IARC, Lyon, FR.
  • Jenkins RA, Guerin MR, Tomkins BA. (2000). The Chemistry of Environmental Tobacco Smoke: Composition and Measurement, Second Edition. pp 77–106, Lewis Publishers, Boca Raton, FL.
  • Jensen JA, Schillo BA, Moilanen MM, Lindgren BR, Murphy S, Carmella S, Hecht SS, Hatsukami DK. (2010). Tobacco smoke exposure in nonsmoking hospitality workers before and after a state smoking ban. Cancer Epidemiol Biomarkers Prev 19:1016–1021.
  • Joseph AM, Hecht SS, Murphy SE, Carmella SG, Le CT, Zhang Y, Han S, Hatsukami DK. (2005). Relationships between cigarette consumption and biomarkers of tobacco toxin exposure. Cancer Epidemiol Biomarkers Prev 14:2963–2968.
  • Joseph AM, Hecht SS, Murphy SE, Lando H, Carmella SG, Gross M, Bliss R, Le CT, Hatsukami DK. (2008). Smoking reduction fails to improve clinical and biological markers of cardiac disease: a randomized controlled trial. Nicotine Tob Res 10:471–481.
  • Kotlyar M, Hertsgaard LA, Lindgren BR, Jensen JA, Carmella SG, Stepanov I, Murphy SE, Hecht SS, Hatsukami DK. (2011). Effect of oral snus and medicinal nicotine in smokers on toxicant exposure and withdrawal symptoms: a feasibility study. Cancer Epidemiol Biomarkers Prev 20:91–100.
  • Le Marchand L, Derby KS, Murphy SE, Hecht SS, Hatsukami D, Carmella SG, Tiirikainen M, Wang H. (2008). Smokers with the CHRNA lung cancer-associated variants are exposed to higher levels of nicotine equivalents and a carcinogenic tobacco-specific nitrosamine. Cancer Res 68:9137–9140.
  • Lee PN. (1999). Uses and abuses of cotinine as a marker of tobacco smoke exposure. In Analytical Determination of Nicotine and Related Compounds and Their Metabolites. (Gorrod JW and Jacob P III Eds.)), pp 669–719, Elsevier, Amsterdam.
  • Lowe FJ, Gregg EO, McEwan M. (2009). Evaluation of biomarkers of exposure and potential harm in smokers, former smokers and never-smokers. Clin Chem Lab Med 47:311–320.
  • Meger M, Meger-Kossien I, Riedel K, Scherer G. (2000). Biomonitoring of environmental tobacco smoke (ETS)-related exposure to 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK). Biomarkers 5:33–45.
  • Mendoza-Baumgart MI, Tulunay OE, Hecht SS, Zhang Y, Murphy S, Le C, Jensen J, Hatsukami DK. (2007). Pilot study on lower nitrosamine smokeless tobacco products compared with medicinal nicotine. Nicotine Tob Res 9:1309–1323.
  • Morse MA, Eklind KI, Toussaint M, Amin SG, Chung FL. (1990). Characterization of a glucuronide metabolite of 4-(methyl-nitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and its dose-dependent excretion in the urine of mice and rats. Carcinogenesis 11:1819–1823.
  • Parsons WD, Carmella SG, Akerkar S, Bonilla LE, Hecht SS. (1998). A metabolite of the tobacco-specific lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in the urine of hospital workers exposed to environmental tobacco smoke. Cancer Epidemiol Biomarkers Prev 7:257–260.
  • Roemer E, Stabbert R, Rustemeier K, Veltel DJ, Meisgen TJ, Reininghaus W, Carchman RA, Gaworski CL, Podraza KF. (2004). Chemical composition, cytotoxicity and mutagenicity of smoke from US commercial and reference cigarettes smoked under two sets of machine smoking conditions. Toxicology 195:31–52.
  • Schick SF, Glantz S. (2007). Concentrations of the carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in sidestream cigarette smoke increase after release into indoor air: results from unpublished tobacco industry research. Cancer Epidemiol Biomarkers Prev 16:1547–1553.
  • Sleiman M, Gundel LA, Pankow JF, Jacob P 3rd, Singer BC, Destaillats H. (2010). Formation of carcinogens indoors by surface-mediated reactions of nicotine with nitrous acid, leading to potential thirdhand smoke hazards. Proc Natl Acad Sci USA 107:6576–6581.
  • Stark MJ, Rohde K, Maher JE, Pizacani BA, Dent CW, Bard R, Carmella SG, Benoit AR, Thomson NM, Hecht SS. (2007). The impact of clean indoor air exemptions and preemption policies on the prevalence of a tobacco-specific lung carcinogen among nonsmoking bar and restaurant workers. Am J Public Health 97:1457–1463.
  • Stepanov I, Hecht SS, Duca G, Mardari I. (2006). Uptake of the tobacco-specific lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone by Moldovan children. Cancer Epidemiol Biomarkers Prev 15:7–11.
  • Stepanov I, Upadhyaya P, Carmella SG, Feuer R, Jensen J, Hatsukami DK, Hecht SS. (2008). Extensive metabolic activation of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in smokers. Cancer Epidemiol Biomarkers Prev 17:1764–1773.
  • Thomas JL, Guo H, Carmella SG, Balbo S, Han S, Davis A, Yoder A, Murphy SE, An LC, Ahluwalia JS, Hecht SS. (2011). Metabolites of a tobacco-specific lung carcinogen in children exposed to secondhand or thirdhand tobacco smoke in their homes. Cancer Epidemiol Biomarkers Prev 20:1213–1221.
  • Tulunay OE, Hecht SS, Carmella SG, Zhang Y, Lemmonds C, Murphy S, Hatsukami DK. (2005). Urinary metabolites of a tobacco-specific lung carcinogen in nonsmoking hospitality workers. Cancer Epidemiol Biomarkers Prev 14:1283–1286.
  • U.S. Department of Health and Human Services. (2006). The Health Consequences of Involuntary Exposure to Tobacco Smoke: A Report of the Surgeon General. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control, Center for Health Promotion and Education, Office on Smoking and Health, Washington, D.C.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.